We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Risk Factor Found for Diabetes

By Biotechdaily staff writers
Posted on 25 Jan 2006
A team of scientists has discovered a variant in a gene on chromosome 10 that is the most significant genetic risk factor found to date for type 2 diabetes (T2D).

In the populations studied, more than one-third carried one copy of the at-risk variant and have an increased risk of around 45%, compared to controls, while 7% were found to carry two copies and have a 141% greater risk. More...
The variant is located in a gene encoding a protein called transcription factor 7-like 2 (TCF7L2).

The researchers, from deCODE Genetics (Reykjavik, Iceland), isolated the gene by following up on the results of a genome-wide linkage scan in Iceland that identified a promising region on chromosome 10. They genotyped 228 microsatellite markers--polymorphic signposts along the genome--in this region in more than 2,000 patients and controls. An analysis of the frequency of different alleles of these markers pinpointed a version of one marker with the gene encoding TCF7L2 that is about 1.5 times more common in patients than in controls. This represents a 50% increase in risk of T2D per copy carried (two copies of each chromosome are in every cell).

The research was repeated in Danish and U.S. subjects, where the at-risk version of the marker was found to confer an increased risk of 41% and 85%, respectively, per copy carried. For all of the cohorts combined, the at-risk allele confers an increased risk of about 45% for those carrying one copy and a 141% increase for those carrying two copies. By utilizing data from the HapMap project, the researchers were able to find a single nucleotide polymorphism (SNP) that correlates almost perfectly with the at-risk microsatellite. The results of the research were published in the January 15, 2006, online edition of Nature Genetics.

"This is a milestone in human genetics,” said senior author Kari Stefansson, CEO of deCode. "A common gene variant conferring elevated risk of T2D has been earnestly sought by the genetics community for many years. Importantly, virtually all of this risk can be captured by looking at a single-letter change in DNA--ideal for the development of a genetic test for assessing individual risk and developing more personalized and effective prevention strategies.”




Related Links:
deCODE Genetics

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.